Generic filters



The company is Shariah Compliant, according to AAOIFI methodology.

CEL-SCI Corporation is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are LEAPS COV-19, CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company is developing an immunotherapy with the potential to treat the coronavirus (COVID-19) using its LEAPS peptide technology.


Debt ÷ Market cap (MC)13.41
Non-Compliant Assets ÷ MC0

Found the Stock You’re Looking For? Open an Account Today!

Opening an account has never been easier! Please fill out the form here and an advisor will be in touch to walk you through the process!

Still have some further questions?